Pioglitazone and sulfonylureas: Effectively treating type 2 diabetes

International Journal of Clinical Practice

Volumn 61, Issue SUPPL. 153, 2007, Pages 20-27

  Hanefeld, M ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; GLICLAZIDE; GLIMEPIRIDE; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA; SULFONYLUREA DERIVATIVE;

ADD ON THERAPY; CARDIOVASCULAR RISK; CELL STRESS; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; GLYCEMIC CONTROL; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PRIORITY JOURNAL; REVIEW; CARDIOVASCULAR DISEASE; DRUG COMBINATION; DRUG EFFECT; HYPERLIPIDEMIA; PATHOPHYSIOLOGY; PHYSIOLOGY;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; HYPERLIPIDEMIAS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 34347225572     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01361.x     Document Type: Review

References (85)

1. Fox KM, Gerber Pharmd RA, Bolinder B et al. Prevalence of inadequate glycaemic control among patients with type 2 diabetes in the United Kingdom general practice research database: a series of retrospective analyses of data from 1998 through 2002. Clin Ther 2006 28 : 388 95.
2. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulphonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49). The UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999 281 : 2005 12.
3. Kahn SE. Clinical review 135: the importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 2001 86 : 4047 58.
4. UKPDS Study Group. UK Prospective Diabetes Study V. Characteristics of newly presenting type 2 diabetic patients: estimated insulin sensitivity and islet β-cell function. Diabetic Med 1988 5 : 444 8.
5. Bell DS, Ovalle F. Outcomes of initiation of therapy with once-daily combination of a thiazolidinedione and a biguanide at an early stage of type 2 diabetes. Diabetes Obes Metab 2004 6 : 363 6.
6. Rosenstock J, Sugimoto D, Strange P et al. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naïve patients. Diabetes Care 2006 29 : 554 9.
7. Buchanan TA, Xiang AH, Peters RK et al. Preservation of pancreatic B-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002 51 : 2796 803.
8. Xiang AH, Peters RK, Kjos SL et al. Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 2006 55 : 517 22.
9. Chiasson JL, Josse RG, Gomis R et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. J Am Med Assoc 2003 290 : 486 94.
10. Ratner RE. An update on the diabetes prevention program. Endocr Pract 2006 12 : 20 4.
11. Hayden MR, Tyagi SC, Kerklo MM, Nicolls MR. Type 2 diabetes mellitus as a conformational disease. JOP 2005 6 : 287 302.
12. Boden G, Laakso M. Lipids and glucose in type 2 diabetes: what is the cause and effect Diabetes Care 2004 27 : 2253 9.
13. Nobel J, Baerlocher MO, Silverberg J. Management of type 2 diabetes mellitus. Role of thiazolidinediones. Can Fam Physician 2005 51 : 683 7.
14. Lebovitz HE. Oral therapies for diabetic hyperglycemia. Endocrinol Metab Clin North Am 2001 30 : 909 33.
15. Luna B, Feinglos M. Oral agents in the management of type 2 diabetes mellitus. Am Fam Physician 2001 63 : 1747 56.
16. Wright A, Burden AC, Paisley RB et al. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002 25 : 330 6.
17. Kahn SE, Haffner SM, Heise MA et al. for the ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006 355 : 2427 43.
18. Van Gaal L, Scheen A. Are all glitazones the same Diabetes Metab Res Rev 2002 18 : S1 S4.
19. Tan MH, Baksi A, Krahulec B et al. Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes. Diabetes Care 2005 28 : 544 50.
20. Aljabri K, Kozak SE, Thompson DM. Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomised trial. Am J Med 2004 116 : 230 5.
21. Charbonnel B, Schernthaner G, Brunetti P et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia 2005 48 : 1093 104.
22. Charbonnel B, Scheen A. Combination therapy with pioglitazone and either metformin or sulfonylurea: glycemic results from PROactive [abstract]. Diabetes 2006 55 : A478.
23. Comaschi MA, Di Pietro C, Fionda A et al. Efficacy and safety of pioglitazone in addition to SU or Met vs FC with Met plus glyburide in T2 diabetes Pts [abstract]. Diabetes 2006 55 : A473 4.
24. Ginis AA, Karamanos B, Charalampidou E et al. Evaluation of changes of glycaemic control and lipid parameters in patients with T2DM after one year of treatment with pioglitazone in combination with metformin or sulfonylurea in a Greek observational study [abstract]. Diabetologia 2006 49 : 490.
25. Hanefeld M, Charbonnel BH, Brunetti P et al. One-year glycemic control with a sulfonylurea plus pioglitazone vs. a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 2004 27 : 141 7.
26. Hohberg C, Luebben G, Pfutzner A et al. Conversion of type 2 diabetic patients treated with a conventional insulin regimen to oral treatment with pioglitazone and glimepiride improves insulin resistance and does not result in an overall deterioration of metabolic control [abstract]. Diabetes 2006 55 : A481.
27. Kipnes MS, Krosnick A, Rendell MS et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 2001 111 : 10 7.
28. Derosa G, Cicero AFG, Gaddi A et al. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. Diabetes Res Clin Pract 2005 69 : 5 13.
29. Del Prato S, Pulizzi N. The place of sulfonylureas in the therapy for type 2 diabetes mellitus. Metabolism 2006 55 : S20 7.
30. Ansar MM, Ansari M. Nitric oxide involvement in pancreatic beta cell apoptosis by glibenclamide. Nitric Oxide 2006 14 : 39 44.
31. Davilli AM, Pontiroli AE, Socci C et al. Human islets chronically exposed in vitro to different stimuli become unresponsive to the same stimuli given acutely: evidence supporting specific desensitization rather than beta-cell exhaustion. J Clin Endocrinol Metab 1992 74 : 7900 4.
32. Hambrock A, de Oliveira Franz CB, Hiller S, Osswald H. Glibenclamide-induced apoptosis is specifically enhanced by expression of the sulfonylurea receptor isoform SUR1 but not by expression of SUR2B or the mutant SUR1 (M1289T). J Pharmacol Exp Ther 2006 316 : 1031 7.
33. Iwakura T, Fujimoto S, Kagimoto S et al. Sustained enhancement of Ca(2+) influx by glibenclamide induces apoptosis in RINm5F cells. Biochem Biophys Res Commun 2000 271 : 422 8.
34. Maedler K, Carr RD, Bosco D et al. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 2005 90 : 501 6.
35. Kimoto K, Suzuki K, Kizaki T et al. Gliclazide protects pancreatic beta-cells from damage by hydrogen peroxide. Biochem Biophys Res Commun 2003 303 : 112 9.
36. Diani AR, Sawada G, Wyse B et al. Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes. Am J Physiol Endocrinol Metab 2004 286 : E116 22.
37. Finegood DT, McArthur MD, Kojwang D et al. β-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes 2001 50 : 1021 9.
38. Higa M, Zhou YT, Ravazzola M et al. Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats. Proc Natl Acad Sci USA 1996 96 : 11513 28.
39. Ishida H, Takizawa M, Ozawa S et al. Pioglitazone improves insulin secretory capacity and prevents the loss of beta-cell mass in obese diabetic db/db mice: possible protection of beta cells from oxidative stress. Metabolism 2004 53 : 488 94.
40. Kawasaki F, Matsuda M, Kanada Y et al. Structural and functional analysis of pancreatic islets preserved by pioglitazone in db/db mice. Am J Physiol Endocrinol Metab 2005 288 : E510 8.
41. Smith SA, Lister CA, Toseland CD et al. Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat. Diabetes Obes Metab 2000 2 : 363 72.
42. Yajima K, Hirose H, Fujita H et al. Combination therapy with PPARgamma and PPARalpha agonists increases glucose-stimulated insulin secretion in db/db mice. Am J Physiol Endocrinol Metab 2003 284 : E966 71.
43. Bell DSH. B-cell rejuvenation with thiazolidinediones Am J Med 2003 115 : 20S 3S.
44. Rhodes CJ. Type 2 diabetes - a matter of beta cell life and death Science 2005 307 : 380 4.
45. Kashyap S, Belfort R, Gastaldelli A et al. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes 2003 52 : 2461 74.
46. Zhou Y, Grill V. Long term exposure to fatty acids and ketones inhibits B-cell functions in human pancreatic islets of Langerhans. J Clin Endocrinol Metab 1995 80 : 1584 90.
47. Buse JB, Tan MH, Prince MJ et al. The effects of oral anti-hyperglycaemic medication on serum lipid profiles in patients with type 2 diabetes. Diabetes Obes Metab 2004 6 : 133 56.
48. Zeender E, Maedler K, Bosco D et al. Pioglitazone and sodium salicylate protect human beta-cells against apoptosis and impaired function induced by glucose and interleukin-1beta. J Clin Endocrinol Metab 2004 89 : 5059 66.
49. Butler AE, Jang J, Gurlo T et al. Diabetes due to a progressive defect in β-cell mass in rats transgenic for human islet amyloid polypeptide (HIP rat). A new model for type 2 diabetes. Diabetes 2004 53 : 1509 16.
50. Hull RL, Shen ZP, Watts MR et al. Long-term treatment with rosiglitazone and metformin reduces the extent of, but does no prevent, islet amyloid deposition in mice expressing the gene for human islet amyloid polypeptide. Diabetes 2005 54 : 2235 44.
51. Lin CY, Gurlo T, Haataja L et al. Activation of peroxisome proliferator-activated receptor-gamma by rosiglitazone protects human islet amyloid polypeptide toxicity by a phosphatidylinositol 3′-kinase-dependent pathway. J Clin Endocrinol Metab 2005 90 : 6678 86.
52. Hanefeld M, Marx N, Pfutzner A et al. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular-risk patients with elevated high sensitivity-CRP: the PIOSTAT study. JACC 2007 49 : 290 7.
53. Rosenblatt S, Miskin B, Glazer NB et al. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis 2001 12 : 413 23.
54. Wallace TM, Levy JC, Matthews DR. An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study. Diabet Med 2004 21 : 568 76.
55. Smith SA, Porter LE, Biswas N et al. Rosiglitazone, but not glyburide, reduces circulating proinsulin and the proinsulin:insulin ratio in type 2 diabetes. J Clin Endocrinol Metab 2004 89 : 6048 53.
56. Buchanan TA, Xiang AH, Peters RK et al. Response of pancreatic beta-cells to improved insulin sensitivity in women at high risk for type 2 diabetes. Diabetes 2000 49 : 782 8.
57. Cavaghan MK, Ehrmann DA, Byrne MM et al. Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest 1997 100 : 530 7.
58. Ovalle F, Bell DSH. Effect of rosiglitazone vs. insulin on the pancreatic β-cell function of subjects with type 2 diabetes. Diabetes Care 2004 27 : 2585 9.
59. Urquhart R, Tan MH, Mariz S et al. Long-term (2-year) effects on HOMA-%S, an estimate of insulin sensitivity, of pioglitazone, gliclazide and metformin as add-on therapies in patients with T2DM [abstract]. Diabetes 2004 53 : A150.
60. Clark HE, Matthews DR. The effect of glimerpiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus. Horm Metab Res 1996 28 : 445 50.
61. Kawamori R, Matsuhisa M, Kinoshita J et al. Pioglitazone enhances splanchic glucose uptake as well as peripheral glucose uptake in non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1998 41 : 35 43.
62. Miyazaki Y, Ferrannini E, Mahankali A et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 2001 24 : 710 9.
63. Tan MH, Glazer NB, Johns D et al. Pioglitazone as monotherapy or in combination with sulfonylurea or metformin enhances insulin sensitivity (HOMA-S or QUICKI) in patients with type 2 diabetes. Curr Med Res Opin 2004 20 : 723 8.
64. Yamasaki Y, Kawamori R, Wasada T et al. Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM. Tohoku J Exp Med 1997 183 : 173 83.
65. Periello G, Pampanelli S, Di Pietro C et al. Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients with type 2 diabetes. Diabet Med 2006 23 : 246 52.
66. Ceriello A, Eckland DJ, Johns D et al. Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes. Diabetes Care 2005 28 : 266 72.
67. Quast U, Stephan D, Bieger S, Russ U. The impact of ATP-sensitive K+ channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardium. Diabetes 2004 53 : S156 64.
68. Simpson SH, Majumdar SR, Tsuyuki RT et al. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ 2006 174 : 169 74.
69. Johnsen SP, Monster TB, Olsen ML et al. Risk and short-term prognosis of myocardial infarction among users of antidiabetic drugs. Am J Ther 2006 13 : 134 40.
70. Ueba H, Kuroki M, Hashimoto S et al. Glimepiride induces nitric oxide production in human coronary artery endothelial cells via a PI3-kinase-Akt dependent pathway. Atherosclerosis 2005 183 : 35 9.
71. Garratt KN, Brady PA, Hassinger NL et al. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1999 33 : 119 24.
72. Scognamiglio R, Avogar A, Vigili Kreutzenberg de S et al. Effect of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in type 2 diabetes. Diabetes 2002 51 : 808 12.
73. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 352 : 837 53.
74. Perez A, Khan M, Johnson T, Karunaratne M. Pioglitazone plus a sulfonylurea or metformin is associated with increased lipoprotein particle size in patients with type 2 diabetes. Diabetes Vasc Dis Res 2004 1 : 44 50.
75. Khan M, Spanheimer R, Shinall S. Lipid and apolipoprotein levels improve with pioglitazone plus sulfonylurea after treatment conversion from rosiglitazone in subjects with type 2 diabetes and dyslipidemia who continue stable statin therapy [abstract]. Diabetologia 2006 49 : 704.
76. Peters Harmel AL, Kendall DM, Buse JB et al. Impact of adjunctive thiazolidinedione therapy on blood levels and glycemic control in patients with type 2 diabetes. Curr Med Res Opin 2004 20 : 215 23.
77. Betteridge DJ, Vergés B. Long-term effects on lipids and lipoproteins of pioglitazone vs. gliclazide addition to metformin and pioglitazone vs. metformin addition to sulfonylurea in the treatment of type 2 diabetes. Diabetologia 2005 48 : 2477 81.
78. Spanheimer R, Tan M, Yates J et al. The effects of long-term pioglitazone therapy on lipid profiles in high-risk type 2 diabetes patients: results from PROactive [abstract]. Diabetologia 2006 49 : 69 70.
79. Torre E, Ponzani P, Menozzi F, Mariz S, Corsi A, Comaschi M. The efficacy and safety of pioglitazone in addition to SU or metformin vs fixed combination of metformin plus glibenclamide on diabetic dyslipidaemia [abstract]. Diabetologia 2006 49 : 493 4.
80. Derosa G, Cicero AFG, D'Angelo A et al. Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride. Hypertens Res 2005 28 : 917 24.
81. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002 106 : 679 84.
82. Marx N, Imhof A, Froehlich J et al. Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation 2003 107 : 1954 7.
83. Mohanty P, Aljada A, Ghanim H et al. Evidence for a potent anti-inflammatory effect of rosiglitazone. J Clin Endocrinol Metab 2004 89 : 2728 35.
84. Pfutzner A, Marx N, Lubben G et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 2005 45 : 1925 3.
85. Derosa G, Cicero AF, Gaddi A et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clin Ther 2004 26 : 744 54.